EBR Systems Revenue and Competitors
Estimated Revenue & Valuation
- EBR Systems's estimated annual revenue is currently $23.6M per year.
- EBR Systems received $50.0M in venture funding in November 2017.
- EBR Systems's estimated revenue per employee is $251,000
- EBR Systems's total funding is $199.9M.
- EBR Systems's current valuation is $344M. (October 2021)
- EBR Systems has 94 Employees.
- EBR Systems grew their employee count by 8% last year.
EBR Systems Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is EBR Systems?
EBR Systems, Inc. is driven to deliver superior treatment for millions of patients suffering from cardiac rhythm diseases by developing safe, clinically superior, cost-effective and reliable therapies using wireless cardiac stimulation. The company's initial product, the WiSE CRT System, is a first-of-its-kind medical device developed to overcome the limitations of traditional Cardiac Resynchronization Therapy (CRT) in heart failure patients by eliminating the need for a lead to the heart's left ventricle and the associated complications of that lead.keywords:Healthcare,Human Resources Hr,Medical Devices,Pharmaceuticals
Number of Employees
Employee Growth %
EBR Systems News
Further, the Micra Transcatheter Pacing System offered by Medtronic ... Cordis, Lepu Medical, Getinge AB, St. Jude Medical and EBR Systems.
Morgans has a 12-month target price of $1.84 on EBR, which is currently trading ~58 cents. EBR EBR Systems Cdi 1:1 US Person Prohibited. Mkt...
Leadless Pacemaker Systems Market Analysis By 2021 -2028 | Top Key Players Abbott Laboratories, Medtronic PLC, EBR Systems Inc.,...
EBR Systems, Inc., a Sunnyvale, Calif.-based developer of a wireless cardiac pacing system for heart failure, raised $30M in funding.
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
EBR Systems Funding
|2015-04-09||$20.0M||Undisclosed||Emergent Medical Partners||Article|
|2017-11-15||$50.0M||Undisclosed||M.H. Carnegie & Co||Article|